David L Wyles

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model
    Edward R Cachay
    Department of Medicine, Owen Clinic, University of California at San Diego, 200 W, Arbor Drive, San Diego, CA, 92103 8681, USA
    AIDS Res Ther 10:9. 2013
  2. doi request reprint Antiviral resistance and the future landscape of hepatitis C virus infection therapy
    David L Wyles
    Division of Infectious Diseases, University of California San Diego, La Jolla, CA, USA
    J Infect Dis 207:S33-9. 2013
  3. doi request reprint Hepatitis C virus drug resistance: implications for clinical management
    David L Wyles
    Division of Infectious Diseases, University of California, San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
    Infect Dis Clin North Am 26:967-78. 2012
  4. pmc Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment
    Edward R Cachay
    Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
    AIDS Res Ther 8:29. 2011
  5. ncbi request reprint Development of herpes simplex virus disease in patients who are receiving cidofovir
    David L Wyles
    Division of Infectious Diseases, University of California, San Diego, CA, USA
    Clin Infect Dis 41:676-80. 2005
  6. pmc Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets
    David L Wyles
    Department of Medicine, Divivion of Infectious Diseases, University of California San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
    J Virol 81:3005-8. 2007
  7. pmc Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors
    David L Wyles
    Division of Infectious Diseases, Department of Medicine, University of California, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
    Antimicrob Agents Chemother 52:1862-4. 2008
  8. pmc Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication
    Nadejda Valiaeva
    Division of Infectious Diseases, University of California, San Diego, USA
    Bioorg Med Chem 19:4616-25. 2011
  9. pmc 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication
    Christian Grünberger
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, USA
    J Infect Dis 197:42-5. 2008
  10. pmc The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons
    David L Wyles
    San Diego Veterans Medical Research Foundation and the Department of Medicine, Division of Infectious Disease, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0676, USA
    Antimicrob Agents Chemother 53:2660-2. 2009

Collaborators

Detail Information

Publications16

  1. pmc Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model
    Edward R Cachay
    Department of Medicine, Owen Clinic, University of California at San Diego, 200 W, Arbor Drive, San Diego, CA, 92103 8681, USA
    AIDS Res Ther 10:9. 2013
    ..Access to Hepatitis C (HCV) care is low among HIV-infected individuals, highlighting the need for new models to deliver care for this population...
  2. doi request reprint Antiviral resistance and the future landscape of hepatitis C virus infection therapy
    David L Wyles
    Division of Infectious Diseases, University of California San Diego, La Jolla, CA, USA
    J Infect Dis 207:S33-9. 2013
    ..Promising results from early stages of interferon-free trials will be reviewed...
  3. doi request reprint Hepatitis C virus drug resistance: implications for clinical management
    David L Wyles
    Division of Infectious Diseases, University of California, San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
    Infect Dis Clin North Am 26:967-78. 2012
    ..Finally, resistance considerations for other classes of inhibitors and the rapidly approaching interferon-free therapeutics regimens are offered...
  4. pmc Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment
    Edward R Cachay
    Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
    AIDS Res Ther 8:29. 2011
    ..abstract:..
  5. ncbi request reprint Development of herpes simplex virus disease in patients who are receiving cidofovir
    David L Wyles
    Division of Infectious Diseases, University of California, San Diego, CA, USA
    Clin Infect Dis 41:676-80. 2005
    ..In vitro resistance to cidofovir has been reported with use of laboratory HSV strains; clinical failure of cidofovir therapy for HSV disease has also been reported with an isolate that was susceptible by in vitro testing...
  6. pmc Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets
    David L Wyles
    Department of Medicine, Divivion of Infectious Diseases, University of California San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
    J Virol 81:3005-8. 2007
    ..These results suggest that combinations of inhibitors with different mechanisms of action should be prioritized for assessment in clinical trials for chronic hepatitis C virus infection...
  7. pmc Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors
    David L Wyles
    Division of Infectious Diseases, Department of Medicine, University of California, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
    Antimicrob Agents Chemother 52:1862-4. 2008
    ..ACH-806 is a hepatitis C virus NS4A inhibitor with a novel mechanism of action and resistance pathway. This compound was synergistic with NS3 protease inhibitors and NS5B nucleoside and nonnucleoside polymerase inhibitors...
  8. pmc Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication
    Nadejda Valiaeva
    Division of Infectious Diseases, University of California, San Diego, USA
    Bioorg Med Chem 19:4616-25. 2011
    ..The most active anti-HIV compound was octadecyloxyethyl 9-(R)-[3-methoxy-2-(phosphonomethoxy)propyl]guanine with an EC₅₀ < 0.01 nanomolar and a selectivity index of > 4.4 million...
  9. pmc 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication
    Christian Grünberger
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, USA
    J Infect Dis 197:42-5. 2008
    ..We formally demonstrate synergistic antiviral activity with 3-drug combinations in this model, further supporting the concept of clinical investigations of combination therapy for HCV infection...
  10. pmc The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons
    David L Wyles
    San Diego Veterans Medical Research Foundation and the Department of Medicine, Division of Infectious Disease, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0676, USA
    Antimicrob Agents Chemother 53:2660-2. 2009
    ..In genotype 1A and 1B replicons analyzed by HCV RNA analysis, ODE-(S)-HPMPA was the most active compound, with EC(50)s of 1.8 and 2.1 microM, respectively...
  11. doi request reprint Rong's numbers: accelerating progress in HCV therapeutic research
    David L Wyles
    Division of Infectious Diseases, University of California, San Diego, San Diego, CA 92093, USA
    Sci Transl Med 2:33ps25. 2010
    ....
  12. pmc Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches
    Sergey M Dibrov
    Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 109:5223-8. 2012
    ..The presence of a well-defined ligand-binding pocket within the highly conserved IRES subdomain IIa holds promise for the development of unique anti-HCV drugs with a high barrier to resistance...
  13. pmc Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA
    Jerod Parsons
    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California, USA
    Nat Chem Biol 5:823-5. 2009
    ....
  14. ncbi request reprint Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection
    David L Wyles
    University of California San Diego, La Jolla, CA, USA
    Top HIV Med 18:132-6. 2010
    ....
  15. pmc Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials
    Lynn E Taylor
    Department of Medicine, Brown University, Providence, Rhode Island, USA
    Clin Infect Dis 52:812-8. 2011
    ..Whether this is occurring across the United States is unknown...
  16. ncbi request reprint Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction
    David L Wyles
    Department of Medicine, Divisions of Infectious Diseases and Clinical Pharmacology, University of Colorado Health Sciences Center, Denver, USA
    Clin Infect Dis 40:174-81. 2005
    ....

Research Grants2

  1. An in vitro system to study antiviral strategies against Hepatitis C virus
    DAVID WYLES; Fiscal Year: 2007
    ..The Description section was not included in the original submission of the amended application. ..